Advertisement

Picture Berlin Partner Berlin-Brandenburg Healthcare Industries Cluster 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Date (ascending)
1 2 3 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Agilent–Univ Duisburg-Essen: analytical technology, 201804– collab with new Agilent sponsored Teaching + Research Center for Separation (TRC) at UDE
Cellestia Biotech–SEVERAL: investment, 201701 seed financing round Series C CHF5.2m from Sotio/PPF Group + private investors
Cellestia Biotech–SEVERAL: investment, <2017 seed financing round Series A CHF0.5m
Cellestia Biotech–SEVERAL: investment, <2017 seed financing round Series B CHF2.3m
Mind NRG–Minerva Neurosciences: investment, before 202008 acquisition of Mind NRG (CH) by Minerva Neurosciences
OTHER–Novartis: investment, 201401 acquisition of biologics manufacturing faciltiy in Longmont CO by AveXis
R-Biopharm–EuroProxima: research antibodies, 201710 acquisition of research antibody line from EuroProxima BV by Progen Biotechnik GmbH
SimplicityBio–TATAA Biocenter: biomarker services, 201610– collab product integration to offer complete biomarker solutions
Brechbühler–Phenomenex: chromatography consumables, 1991–201708 distribution in Switzerland by Brechbühler TERMINATED 9/17 1991-01-01
Hoechst–Clariant: investment, 1997 acquisition of Hoechst Speciality Chemical Business by Clariant 1997-01-01
Eurofins–SEVERAL: investment, 199710 IPO 1997-10-24
Boehringer Mannheim–Roche: investment, 1998 acquisition by Roche 1998-01-01
Biocentric–Hain Lifescience: molecular diagnostics, 2001– exclusive distributor of Hain products in France 2001-01-01
Selexis–SEVERAL: investment, 2001 seed financing CHF100k 2001-01-01
Grabner Instruments–Chandler Instruments: investment, 2002 acquisition of Grabner by Chandler 2002-01-01
Chandler Instruments–AMETEK: investment, 2003 acquisition of Chandler Instruments by AMETEK 2003-01-01
Actelion–Enamine: chemical compound library, 2005– collab supply of screening compound library to Actelion 2005-01-01
Umetrics–MKS Instruments: investment, 2006 acquisition by MKS Instruments 2006-01-01
BioNTech–SEVERAL: investment, 2008 seed financing round 2008-01-01
Isoprime–Elementar: investment, 2008 acquisition of Isoprime Ltd by Elementar Analysensysteme GmbH 2008-01-01
Denali Therapeutics–Evotec: CNS drug discovery, 201608 strategic collab existent 2008-08-25
Denali Therapeutics–Roche: LRRK2 inhibitors, 201608 license ww excl existent to develop + commericalize LRRK2 inhibitors from Genentech 2008-08-25
Probiodrug–Bellevue: investment, 200911 financing round Series B totalling €36m incl new + lead investors BB Biotech + EdRIP 2009-11-02
Probiodrug–Biogen Idec: investment, 200911 financing round Series B totalling €36m incl new + co-investor Biogen Idec New Ventures 2009-11-02
Probiodrug–LCF Rothschild: investment, 200911 financing round Series B totalling €36m incl new + lead investors BB Biotech + EdRIP 2009-11-02
Probiodrug–Life Sciences Partners: investment, 200911 financing round Series B totalling €36m incl new + co-investor LSP 2009-11-02
Roche–Novimmune: therapeutic antibody, 201007– excl license to discover + develop ABs targeting IL-17 pathway for autoimmune diseases Genentech 2010-07-01
Poxel–LCF Rothschild: investment, 201007 financing round Series A totalling €16m incl lead investor EdRIP 2010-07-08
JnJ–Molecular Partners: DARPins, 2011–201610 collab + license DARPin targeting IL-13 + IL-17 against pulmonary disease TERMINATED 10/16 2011-01-01
Meiji Seika Kaisha–Newron: safinamide, 2011– license to develop + manufacture + commercialise safinamide in Asia to Meiji Seika Pharma 2011-01-01
Pfizer–Kohlberg Kravis Roberts: investment, 2011 acquisition of Capsugel from Pfizer by KKR 2011-01-01
Rebiotix–SEVERAL: investment, 2011 seed financing round $5m 2011-01-01
Xencor–Selexis: cell line development, 2011– supply service agreem for SUREtechnology for developm of multi-specific antibodies 2011-01-01
Genoptix–Novartis: investment, 201701–201703 DIVESTMENT sale €na of Genoptix (excl biopharma business) to Ampersand + 1315 Capital + new managers 2011-01-24
Acacia Pharma–Gilde Investment: investment, 201103 financing round Series A totalling $10m incl existing investor Gilde Healthcare 2011-03-31
Acacia Pharma–Lundbeck: investment, 201103 financing round Series A totalling $10m incl new investor Lundbeckfond Ventures 2011-03-31
Acacia Pharma–SEVERAL: investment, 201103 financing round Series A $10m from new investor Lundbeckfond Ventures + existing investor Gilde Healthcare 2011-03-31
Bayer–X-Chem: small-molecule drug discovery, 2012– collab research using DEX technology 2012-01-01
Gilupi–Viroad: investment, 2012 investment in connnection w strategic partnership making Viroad largest shareholder of Gilupi 2012-01-01
JnJ–Phenex: RORgt inhibitors, 2012– collab r+d up to $135m for chronic inflammatory + autoimmune disease w Janssen Biotech 2012-01-01
KBI BioPharma–Selexis: cell line development, 2012– supply service use of cell lines created using SUREtechnology platform by KBI 2012-01-01
Qtis/e–Xeltis: investment, 2012 merger of Qtis/e with Xeltis 2012-01-01
Selexys Pharmaceuticals–Novartis: investment, 201611 acquisition by Novartis for up to $665m upfront + acquisition + milestone payments 2012-01-01
Viroad–Gilupi: diagnostic device, 2012 collab strategic partnership incl investment making Viroad largest shareholder of Gilupi 2012-01-01
B Braun–CeGaT: personalised medicine, 201201– collab strategic partnership to expand + internationalise CeGaT’s business 2012-01-31
Roche–AC Immune: therapeutic antibodies, 201206– license excl for anti-Tau program for Alzheimer’s disease to Genentech 2012-06-01
PlasmidFactory–Sirion Biotech: gene delivery technology, 201212– collab pronotion of AAV vectors for preclinical ersearch 2012-12-04
ABF–Genedata: bioinformatics, 2013– supply use of Genedata Selector by AB Enzymes for strain genome data management 2013-01-01
BioNTech–MAB Discovery: antibody technology, 2013– collab mAb generation using technology of MAB Discovery 2013-01-01
Boehringer–Qiagen: molecular companion diagnostics, 2013 collab existent incl therascreen EGRF RGQ PCR Kit for Giotrif 2013-01-01
Kaiser Optical Systems–Endress+Hauser: investment, 2013 acquisition by Endress+Hauser 2013-01-01
Allecra Therapeutics–EMBL: investment, 201304 financing round Series A totalling €15m incl co-investor EMBL Ventures 2013-04-18
Allecra Therapeutics–Forbion: investment, 201304 financing round Series A totalling €15m incl co-lead investor Forbion 2013-04-18
Allecra Therapeutics–LCF Rothschild: investment, 201304 financing round Series A totalling €15m incl co-lead investor EdRIP 2013-04-18
Gardner Denver–Kohlberg Kravis Roberts: investment, 201307 acquisition 100% for $3.9b incl assumption of debt 2013-07-16
Polymedco–Epigenomics: molecular diagnostics, 201310– collab joint commercialisation of Epi proColon test in North America 2013-10-02
Mission Therapeutics–Roche: investment, 201311 financing round Series B totalling £20m incl existing investor Roche Venture Fund 2013-11-18
Eloxx Pharmaceuticals–SEVERAL: investment, 201311 initial closing of 1st financing round with Roche + Pontifax 2013-11-21
Sirion Biotech–Cevec: cell lines, 201312– license €na to CAP cell lines for expression of AAV vectors 2013-12-19
CeeTox–Cyprotex: investment, 201401 acquisition of assets + business of CeeTox by Cyprotex 2014-01-01
Horizon Discovery–ERS Genomics: CRISPR technology, 2014– license ww non-excl to Horizon 2014-01-01
Provecs–Cevec: rec protein production technology, 2014– license to CAP GT technology for cancer immunotherapy 2014-01-01
Rebiotix–SEVERAL: investment, 2014 financing round Series B $25m 2014-01-01
Sirion Biotech–LaVoieHealthScience: public relations, 2014– supply service US PR/IR 2014-01-01
Tusk Therapeutics–Droia: investment, 201809 existent majority shareholder + founding investor Droia Oncology Ventures 2014-01-01
Synaffix–Aravis: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–BioGeneration Ventures: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–BOM Capital: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–Merck (DE): investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Roche–Oryzon Genomics: LSD1 inhibitors, 201605–201707 collab extension developm of ORY-1001 TERMINATED 7/17 2014-04-07
Essen BioScience–SFW Capital Partners: investment, 201405 strategic investment in Essen BioScience by SFW 2014-04-15
Novartis–Ophthotech: pegpleranib, 201405– excl license + commercialisation agreem outside of US 2014-05-01
B Braun–CeGaT: personalised medicine, 201406 collab establishment of B Braun CeGaT LLC in Pennsylvania 2014-06-01
AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie 2014-07-01
Geisinger–Indivumed: tissue bank, 201407– collab to create cancer research biobanks at Geisinger + Indivumed 2014-07-15
Riboxx–SEVERAL: investment, 201407–201501 crowdfunding €1m via Seedmatch 2014-07-30
i3 Membrane–SEVERAL: investment, 201408 investment by HTGF + Innovationsstarter Fonds Hamburg 2014-08-01
Corgenix Medical–Orgentec: investment, 201409–201503 acquisition of Corgenix for $16m in cash by Orgentec Diagnostika 2014-09-01
Ipsen–MHH: rec botulinum neurotoxin, 201409– collab r+d with Thomas Binz at Institute for Physiological Chemistry at MHH 2014-09-01
Roche–NewLink Genetics: cancer drugs, 201410– collab drug discovery IDO/TDO inhibitors with Genentech 2014-10-16
Pepperprint–Sciomics: microarray technology, 201411– collab distribution + marketing for antibody characterisation + biomarker discovery 2014-11-18
Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana 2014-12-01
Annexon–Clarus Ventures: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Clarus Ventures 2014-12-15
Annexon–Novartis: investment, 201412 financing round Series A-1 totaliing $34m incl lead investor NVF 2014-12-15
Annexon–Satter Investment Management: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Satter 2014-12-15
Annexon–SEVERAL: investment, 201412 financing round Series A-1 $34m led by NVF + incl Satter Investment + Clarus Ventures 2014-12-15
Pieris–Ally Bridge Group: investment, 201412 private placement totalling $13.56m incl investor ABG 2014-12-18
Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF 2015-01-01
Biocentric–Hain Lifescience: investment, 2015 acquisition of Biocentric by Hain 2015-01-01
EffRx–SEVERAL: investment, 201501 financing round CHF2.3m from existing investors 2015-01-01
GreenBone–SEVERAL: investment, 2015 seed financing round €3m from ZernikeMeta Ventures + Italian Angels for Growth + private investors 2015-01-01
IFM Therapeutics–Atlas Venture: investment, 2015 seed funding by Atlas Venture 2015-01-01
Jecure Therapeutics–Versant Ventures: investment, 2015 seed financing from founding investor Versant Ventures 2015-01-01
KBI BioPharma–JSR Corp: investment, 2015 acquisition of KBI BioPharma Inc by JSR Corp 2015-01-01
Kurma–SEVERAL: investment, 2015 final closing €35m of Kurma Diagnostics Fund (KDx) 2015-01-01
Novartis–Fraunhofer: cell therapy production, 201501– collab developm of production capacity for Kymriah in Europe at Fraunhofer IZI 2015-01-01
Novartis–Fraunhofer: cell therapy production, 201808– service supply production of Kymriah in Europe by Fraunhofer IZI 2015-01-01
Numares–SHS: investment, 2015 existent SHS Gesellschaft für Beteiligungsmanagement is main shareholder 2015-01-01
Oncgnostics–MDxHealth: PCR technology, 201501– license ww non-excl for MSP technology for cervical cancer diagnostics to Oncgnostics 2015-01-01
Proteomedix–SEVERAL: investment, 201501 2nd closing of financing round Series B CHF1m bringing total round to CHF4.2m 2015-01-01
1 2 3 ... 29 30 31  next pagenext page



Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px

» top